NCT00002407已完成不适用
A Randomized Open-Label Strategic Study to Evaluate the Safety and Efficacy of 3 Different Convergent and Divergent Drug Combination Therapies in Anti-Retroviral Naive HIV-1 Infected Patients With CD4+ Counts Above 200/mm3
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to see if it is safe and effective to give one of three different triple-drug combinations to HIV-infected patients who have never been treated with anti-HIV drugs.
详细描述
In this open-label, strategic study patients are evaluated at Weeks 0, 1, 2, 4, 8, 12 to Week 48 after being treated on one of the following regimens:
Stavudine (d4T) + Didanosine (ddI) + Lamivudine (3TC) or d4T + ddI + Indinavir or d4T + ddI + Nevirapine.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Diagnosed asymptomatic HIV infection.
- •HIV-1 RNA greater than 500 copies/ml.
- •CD4+ T-cell count greater than 200/mm
- •Never received antiretroviral therapy.
排除标准
- •Co-existing Condition:
- •Severe non-HIV-related disease.
- •Patients with the following prior conditions are excluded:
- •History of neuropathy.
- •Prior Medication:
- •Investigational drug within 1 month prior to study.
- •Immunomodulatory drug within 1 month prior to study.
- •Prior Treatment:
- •Radiation therapy within past month.
- •Chemotherapy within past month.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
The Comparison of Three Different Immunosuppressant Regimens in Kidney Transplant Recipients.Kidney TransplantNCT00275522Mayo Clinic16
Unknown
4 期
Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received TreatmentHIV InfectionsNCT00005017Glaxo Wellcome300
已完成
3 期
Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)Attention Deficit Hyperactivity DisorderNCT00568685Eli Lilly and Company153
已完成
3 期
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic PsoriasisPsoriasisNCT03022045AbbVie18
已完成
3 期
A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaNCT02005471Hoffmann-La Roche389